AXGN
Price
$36.68
Change
+$0.20 (+0.55%)
Updated
Oct 22 closing price
Capitalization
2.15B
6 days until earnings call
Intraday BUY SELL Signals
ECOR
Price
$7.41
Change
+$0.06 (+0.82%)
Updated
Oct 22 closing price
Capitalization
66.81M
13 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AXGN vs ECOR

AXGN vs ECOR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
AXGN vs. ECOR commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXGN is a StrongBuy and ECOR is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for AXGN with price predictions
Oct 22, 2026

AXGN in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 01, 2026

AXGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 25 of 30 cases where AXGN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AXGN's RSI Oscillator exited the oversold zone, 20 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 42 of 52 cases where AXGN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.

The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on AXGN as a result. In 69 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.

The Moving Average Convergence Divergence (MACD) for AXGN just turned positive on October 20, 2026. Looking at past instances where AXGN's MACD turned positive, the stock continued to rise in 37 of 47 cases over the following month. The odds of a continued upward trend are 79%.

Following a +1.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXGN advanced for three days, in 271 of 329 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Bearish Trend Analysis

AXGN moved below its 50-day moving average on September 22, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for AXGN crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

The Aroon Indicator for AXGN entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.398) is normal, around the industry mean (2.874). P/E Ratio (-54.746) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). AXGN has a moderately high Dividend Yield (0.109) as compared to the industry average of (0.009). P/S Ratio (8.961) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 39 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. AXGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for ECOR with price predictions
Oct 22, 2026

ECOR's RSI Indicator remains in oversold zone for 7 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

ECOR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ECOR as a result. In 81 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.

The Moving Average Convergence Divergence Histogram (MACD) for ECOR turned negative on September 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 42 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

ECOR moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ECOR crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ECOR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

The Aroon Indicator for ECOR entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ECOR's P/B Ratio (-23.945) is slightly lower than the industry average of (2.874). P/E Ratio (-4.491) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (2.571) is also within normal values, averaging (40.124).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. ECOR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ECOR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

FUNDAMENTALS RATINGS
AXGN vs ECOR: Fundamental Ratings
AXGN
ECOR
OUTLOOK RATING
1..100
6250
VALUATION
overvalued / fair valued / undervalued
1..100
4
Undervalued
20
Undervalued
PROFIT vs RISK RATING
1..100
39100
SMR RATING
1..100
95100
PRICE GROWTH RATING
1..100
5058
P/E GROWTH RATING
1..100
3166
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AXGN's Valuation (4) in the Medical Specialties industry is in the same range as ECOR (20). This means that AXGN’s stock grew similarly to ECOR’s over the last 12 months.

AXGN's Profit vs Risk Rating (39) in the Medical Specialties industry is somewhat better than the same rating for ECOR (100). This means that AXGN’s stock grew somewhat faster than ECOR’s over the last 12 months.

AXGN's SMR Rating (95) in the Medical Specialties industry is in the same range as ECOR (100). This means that AXGN’s stock grew similarly to ECOR’s over the last 12 months.

AXGN's Price Growth Rating (50) in the Medical Specialties industry is in the same range as ECOR (58). This means that AXGN’s stock grew similarly to ECOR’s over the last 12 months.

AXGN's P/E Growth Rating (31) in the Medical Specialties industry is somewhat better than the same rating for ECOR (66). This means that AXGN’s stock grew somewhat faster than ECOR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AXGNECOR
RSI
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 1 day ago
82%
N/A
Declines
ODDS (%)
Bearish Trend 9 days ago
81%
Bearish Trend 2 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
78%
Aroon
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
86%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (AXGN: $36.48 vs. ECOR: $7.35)
Brand notoriety: AXGN and ECOR are both not notable
Both companies represent the Medical/Nursing Services industry
Current volume relative to the 65-day Moving Average: AXGN: 94% vs. ECOR: 56%
Market capitalization -- AXGN: $2.15B vs. ECOR: $66.81M
AXGN [@Medical/Nursing Services] is valued at $2.15B. ECOR’s [@Medical/Nursing Services] market capitalization is $66.81M. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $837 to $173.92B. The average market capitalization across the [@Medical/Nursing Services] industry is $5.76B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AXGN’s FA Score shows that 2 FA rating(s) are green while ECOR’s FA Score has 1 green FA rating(s).

  • AXGN’s FA Score: 2 green, 3 red.
  • ECOR’s FA Score: 1 green, 4 red.
According to our system of comparison, AXGN is a better buy in the long-term than ECOR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AXGN’s TA Score shows that 6 TA indicator(s) are bullish while ECOR’s TA Score has 4 bullish TA indicator(s).

  • AXGN’s TA Score: 6 bullish, 4 bearish.
  • ECOR’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, AXGN is a better buy in the short-term than ECOR.

Price Growth

AXGN (@Medical/Nursing Services) experienced а +3.81% price change this week, while ECOR (@Medical/Nursing Services) price change was -10.37% for the same time period.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.62%. For the same industry, the average monthly price growth was -10.72%, and the average quarterly price growth was -10.29%.

Reported Earning Dates

AXGN is expected to report earnings on Oct 28, 2026.

ECOR is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Medical/Nursing Services (-1.62% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

View a ticker or compare two or three
AXGN
Daily Signal:
Gain/Loss:
ECOR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

AXGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AXGN has been loosely correlated with XRAY. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if AXGN jumps, then XRAY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AXGN
1D Price
Change %
AXGN100%
+0.55%
XRAY - AXGN
36%
Loosely correlated
+4.63%
ITGR - AXGN
31%
Poorly correlated
-0.11%
CLPT - AXGN
31%
Poorly correlated
N/A
GMED - AXGN
31%
Poorly correlated
+3.79%
ICUI - AXGN
30%
Poorly correlated
+4.66%
More

ECOR and

Correlation & Price change

A.I.dvisor tells us that ECOR and SENS have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ECOR and SENS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ECOR
1D Price
Change %
ECOR100%
+0.82%
SENS - ECOR
30%
Poorly correlated
-7.15%
QDEL - ECOR
29%
Poorly correlated
-4.26%
PFSA - ECOR
28%
Poorly correlated
+20.11%
AXGN - ECOR
26%
Poorly correlated
+0.55%
BWAY - ECOR
26%
Poorly correlated
-4.51%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
NVDQ9.270.73
+8.55%
T-Rex 2X Inverse NVIDIA Daily Target ETF (NVDQ)
IHAK71.040.89
+1.27%
iShares Cybersecurity & Tech ETF (IHAK)
IBTQ24.150.26
+1.11%
iShares iBonds Dec 2035 Term Treasury ETF (IBTQ)
NXPX10.58N/A
N/A
Tradr 2X Long NXPI Daily ETF (NXPX)
SPYC45.02-0.82
-1.78%
Simplify US Equity PLUS Convexity ETF (SPYC)